Founders Hall
Seattle, WA
Wilson Sonsini partner Eva Yin will join a panel on "Healthcare Inefficiency and Drug Discovery: Reality vs. Hype" at the 2025 Seattle AI Week on October 27, 2025. The panel will explore where healthcare spending is most inefficient and how artificial intelligence is reshaping drug discovery. Panelists will share complementary perspectives—ranging from big-picture analyses of healthcare financing and investor priorities in life sciences and AI, to industry insights on commercializing new therapies. For more information and to register, please visit the event website.
Jasper Vera
jvera@wsgr.com
Eva Yin, Ph.D., M.P.H., is a partner in Wilson Sonsini Goodrich & Rosati’s FDA regulatory, healthcare, and consumer products practice. Her practice includes conducting FDA and healthcare regulatory due diligence for corporate transactions; providing legal counsel to manufacturers regarding FDA approval/clearance for various products—including medical devices, mobile apps, and drugs, FDA compliance, regulation of promotional materials and labeling, and manufacturer compliance under federal and state healthcare laws, e.g., the federal Anti-Kickback Statute (AKS), False Claims Act (FCA), Sunshine Act, state licensing laws, corporate practice of medicine, etc.; reviewing contracts and compliance policies for manufacturers; and providing legal analysis and risk assessment of business models and fee arrangements involving patient assistance programs, healthcare professionals, or hospitals/clinics under federal and state healthcare laws and regulations.